Journey Medical Corporati... (DERM)
| Bid | 5.72 |
| Market Cap | 133.91M |
| Revenue (ttm) | 58.76M |
| Net Income (ttm) | -18.65M |
| EPS (ttm) | -0.92 |
| PE Ratio (ttm) | -6.97 |
| Forward PE | -67.67 |
| Analyst | Buy |
| Ask | 6.6 |
| Volume | 228,591 |
| Avg. Volume (20D) | 56,855 |
| Open | 5.80 |
| Previous Close | 5.74 |
| Day's Range | 5.73 - 6.60 |
| 52-Week Range | 2.85 - 6.89 |
| Beta | 0.97 |
About DERM
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; X...
Analyst Forecast
According to 2 analyst ratings, the average rating for DERM stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 56.00% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · seekingalpha.com
Journey Medical Corporation: Emrosi's Launch Could Be A Turning PointJourney Medical's future hinges on Emrosi™, a new formulation of minocycline for rosacea, showing superior efficacy over Oracea® in Phase III trials. Despite current financial challenges and a need fo...